Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15104833 | 0.90 | RAB9A (0.57) | RAB9ASMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL1415165 | 0.81 | SMN1; SMN2 (0.47) | RAB9ASMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL15033663 | 0.80 | RAB9A (0.60) | RAB9ASMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL200831 | 0.80 | MAPK1 (0.63) | RAB9ASMN1; SMN2CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL407138 | 0.79 | ALDH1A1 (0.62) | RAB9ASMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL11441588 | 0.78 | CYP1A2 (0.47) | RAB9ASMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL28620570 | 0.78 | MAPK1 (0.47) | RAB9ASMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL31189136 | 0.78 | RAB9A (0.54) | RAB9ASMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL526575 | 0.78 | RAB9A (0.54) | RAB9ASMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL23400622 | 0.76 | LMNA (0.54) | RAB9ASMN1; SMN2CYP1A2CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9035070-B2 | Process for the preparation of 1-aryl-pyrazol-3-one intermediates useful in the synthesis of sigma receptors inhibitors | Esteve Química, S.A. (ES) | 2015-05-19 | — | — | US | disclosed |
| EP-2598469-B1 | PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS | ESTEVE QUÍMICA S A (ES) | 2014-07-23 | — | — | EP | disclosed |
| US-20130184472-A1 | Process for the Preparation of 1-ARYL-PYRAZOL-3-ONE Intermediates Useful in the Synthesis of SIGMA Receptors Inhibitors | ESTEVE QUIMICA, S.A. (ES) | 2013-07-18 | — | — | US | disclosed |
| EP-2598469-A1 | PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS | Esteve Química, S.A. (ES) | 2013-06-05 | — | — | EP | disclosed |
| EP-2418192-A1 | Intermediates for the preparation of 1-aryl-pyrazol-3-one compounds useful as sigma receptors inhibitors | Esteve Química, S.A. (ES) | 2012-02-15 | — | — | EP | disclosed |
| WO-2012013755-A1 | PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS | Esteve Química, S.A. (ES) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184472-A1 | Process for the Preparation of 1-ARYL-PYRAZOL-3-ONE Intermediates Useful in the Synthesis of SIGMA Receptors Inhibitors | SIGMAR1, OPRK1, OPRM1 | RAB9A 4018/4885SMN1; SMN2 3992/4885CYP1A2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.